Recce Pharmaceuticals Ltd. announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, Copolymer and Method for Treatment of Bacterial Infection, for its anti-infectives, with expiry in 2035. This is the final of Recce?s wholly-owned patents granted for family two, with the Company now patent-protected in all major pharmaceutical markets globally. The Chinese patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), including their methods of manufacture, administration, and application to treat a broad range of common human infections.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.57 AUD | -1.72% | -1.72% | +6.54% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.54% | 78.8M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+12.94% | 238B | |
+7.01% | 204B | |
-6.50% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration